Synageva's LAL deficiency drug wins breakthrough designation from FDA

05/21/2013 | American City Business Journals

The FDA granted breakthrough therapy status to Synageva BioPharma's experimental drug sebelipase alfa, or SBC-102, as a treatment for early onset lysosomal acid lipase deficiency, also known as Wolman disease. The drug is currently in clinical trials against both early onset and late onset LAL deficiency. Sebelipase alfa previously won orphan designation and fast track status from the FDA.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN